GLPG1690 clinical trials
Also written GLPG1690 and ziritaxestat.
How each study uses GLPG1690 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses GLPG1690 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedPhase 3Galapagos NVNCT03733444Written as GLPG1690
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedPhase 3Galapagos NVNCT03711162Written as GLPG1690
- A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisTerminatedPhase 2Galapagos NVNCT03976648Written as GLPG1690
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisCompletedPhase 2Galapagos NVNCT03798366Written as GLPG1690
- Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Galapagos NVNCT02738801Written as GLPG1690 600 mg QD
- A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an InjectionCompletedPhase 1Galapagos NVNCT03787186Written as GLPG1690 film-coated tablets
- A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy VolunteersCompletedPhase 1Galapagos NVNCT03515382Written as GLPG1690
- Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or TabletCompletedPhase 1Galapagos NVNCT03143712Written as GLPG1690
- First-in-Human Single and Multiple Dose of GLPG1690CompletedPhase 1Galapagos NVNCT02179502Written as GLPG1690 single ascending doses